Galactose-Fucose Monosaccharide Composition for Re-Epithelialization

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing wound and lesion treatments, including polysaccharides, lack efficiency in promoting re-epithelialization and healing, and may have stability and absorption issues due to the absence of necessary enzymes in epithelial tissues.

Innovation Solution

Compositions comprising galactose and fucose in monosaccharide form are used to promote re-epithelialization and treat lesions, leveraging their natural compatibility and enzymatic accessibility in epithelial tissues.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If polysaccharides are used for treating wounds and lesions, then the compositions have structural integrity and stability, but they lack enzymatic accessibility and absorption efficiency in epithelial tissues

Engineering Contradiction:

Improvestructural integrityVSAvoidenzymatic accessibility

Core Design Contradiction:

Stability of the object's compositionVSReliability

Solution Approach 1:

The patent segments polysaccharides into their constituent monosaccharide units (galactose and fucose). This segmentation breaks down the complex polymeric structures into simpler, enzymatically accessible monomeric forms that can be directly utilized by epithelial cells for re-epithelialization, resolving the contradiction between structural integrity and enzymatic accessibility.

Inventive Principle:

Principle #1Segmentation

2Strength

If polysaccharides are used for wound treatment, then the compositions provide structural support, but they exhibit poor absorption and utilization by epithelial cells

Engineering Contradiction:

Improvestructural supportVSAvoidabsorption efficiency

Core Design Contradiction:

StrengthVSProductivity

Solution Approach 1:

By segmenting polysaccharides into monosaccharides, the patent creates molecules with significantly improved cellular uptake and metabolic utilization. Epithelial cells can directly absorb and utilize galactose and fucose monosaccharides for energy and biosynthesis, thereby resolving the contradiction between structural support and absorption efficiency.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent changes the molecular size parameter from large polysaccharide polymers to small monosaccharide units. This parameter change dramatically improves cellular permeability and absorption efficiency while maintaining the beneficial biological effects through the combined action of galactose and fucose.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If polysaccharides are degraded into monosaccharides, then enzymatic accessibility and absorption improve, but the viscous properties necessary for hydrogel formation are lost

Engineering Contradiction:

Improveenzymatic accessibilityVSAvoidloss of viscous properties

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses hydroxyethyl cellulose as an intermediary substance to provide the necessary viscous and gel-forming properties. This intermediary component compensates for the loss of viscosity that would otherwise occur when polysaccharides are degraded to monosaccharides, allowing the formulation to maintain hydrogel characteristics while containing the active monosaccharide ingredients.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250367224A1Galactose and fucose monosaccharides for re-epithelialization and treating lesions

Publication Date: 2025.12.04 PATHOBLOCK THERAPEUTICS GMBH & CO KG

AI summary

Disclosed is a composition comprising galactose and fucose in monosaccharide form for use as a promotor of tissue re-epithelialization.